- Home
- MDGL vs ASND Comparison
MDGL vs ASND Comparison
Compare MDGL & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | ASND |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 13.6B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MDGL | ASND |
|---|---|---|
| Price | $442.20 | $227.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $674.45 | $279.50 |
| AVG Volume (30 Days) | 320.8K | ★ 613.6K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.70 | $98.02 |
| Revenue Next Year | $46.88 | $43.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $265.00 | $124.06 |
| 52 Week High | $615.00 | $248.60 |
Technical Indicators
Market Signals| Indicator | MDGL | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 47.71 |
| Support Level | $416.43 | $190.49 |
| Resistance Level | $446.51 | $229.94 |
| Average True Range (ATR) | 15.54 | 8.34 |
| MACD | 3.66 | -1.63 |
| Stochastic Oscillator | 67.00 | 18.40 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.